{"url_path":"/sec/psnl/8-k/2026-05-13/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1527753/0001193125-26-221574-index.html","accession_number":"0001193125-26-221574","cik":"0001527753","ticker":"PSNL","issuer_name":"Personalis, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1527753/0001193125-26-221574-index.html","primary_entity_key":"0001527753","primary_entity_name":"Personalis, Inc."},"word_count":86,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn May12, 2026, the Centers for Medicare & Medicaid Services Molecular Diagnostics Program expanded Medicare coverage for our ultrasensitive NeXT Personal® test to include immunotherapy monitoring for patients with late-stage solid tumors.\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nDate: May 13, 2026\n\nPersonalis, Inc.\n\n \n\nBy:\n\n/s/ Aaron Tachibana\n\nAaron Tachibana\n\nChief Financial Officer and Chief Operating Officer"}